BioWorld

Oct. 26, 2006

VaxInnate Raises $40M Via Series C For TLR Flu Work

Continuing the history of lucrative deals based on Toll-like receptor (TLR) platforms, VaxInnate Corp. raised $40 million in a Series C financing to move its TLR-based flu vaccines into the clinic. (BioWorld Today) Read More

Forest's Phase IIb/III Stroke Compound On Clinical Hold

Forbes Medi-Tech Expanding Pipeline, Acquiring TheraPei

Cadence IPO's Net: $48.5M For Pair Of Phase III Drugs

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

Neutrophils put the brakes on fat loss

BioWorld Science

Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Peptidream reveals milestone in Alnylam collaboration

BioWorld Science

Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...